SecBot SecBot
PRESS-RELEASE ·Filed Apr 27, 2026

TSHA

Taysha Gene Therapies, Inc.
BULLISH
Impact 6/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

Monitor for longer-term clinical data from REVEAL Phase 1/2 expected later this quarter, which will be a more significant catalyst. ASGCT presentation (May 11-15) could drive near-term upside.

DirectionBullish
Confidencehigh
Horizondays

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.30
T+0 close · Apr 27, 2026 · via day close
Latest settled
−7.46%
T+60 · $5.83
Vs SPY
−11.45%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 28 $6.30entry
  2. T+1 · 7mo ago +0.87%α +0.88% · $6.36
  3. T+5 · 7mo ago +5.40%α +3.71% · $6.64
  4. T+20 · 6mo ago −11.27%α −16.74% · $5.59
  5. T+60 · 4mo ago −7.46%α −11.45% · $5.83
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher MeCP2 expression vs. ssAAV9 and miniMeCP2 is functionally comparable to full-length MeCP2, supporting its Rett syndrome gene therapy design. Data will be presented at ASGCT Annual Meeting (May 11-15, 2026), with longer-term clinical data from REVEAL Phase 1/2 expected later this quarter.

Key Facts

  • scAAV9 enabled ~30-fold higher MeCP2 expression compared to ssAAV9 in neuronal cells
  • MiniMeCP2 protein demonstrated functional comparability to full-length MeCP2 across molecular and biochemical assays
  • Data support translational potential of TSHA-102's construct design for lumbar IT administration
  • Longer-term safety and efficacy data from Part A REVEAL Phase 1/2 expected later this quarter

Financial Impact

Preclinical data validation; no financial impact disclosed.

Risk Factors

  • Clinical trial risks: efficacy/safety data may not replicate preclinical findings
  • Regulatory risks: FDA approval uncertain
  • Funding risk: clinical-stage biotech may require additional capital

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
95% bullish (20 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3282099

Track record

14 reports on TSHA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
  2. Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
  3. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
  4. Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
  5. Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
  6. Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
  7. Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
  8. May 6, 202627w ago 8-K Neutral 5/10 No price data
  9. May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
  10. Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
Showing 10 of 14

US Market Status

Market Closed · Opens in 5h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 27, 2026